I schemic heart disease is the leading cause of death in Europe and the US 1 and represents a huge socioeconomic burden. With improved treatment strategies, patient mortality is decreasing, yet acute post-infarct-related heart failure (HF) because of infarct expansion remains a major problem, 2 lacking targeted molecular therapy. Therefore, better understanding of the infarct healing process and the consequent remodeling may result in new treatment options.
cells are recruited into the myocardium to digest necrotic cardiomyocytes. 3, 4 The initial phase is followed by a proliferative phase, where new vessels are formed and new extracellular matrix is deposited by myofibroblasts. 5 The latter is necessary to maintain tensile strength and promoting this event is beneficial to prevent early adverse remodeling and the progression to HF. In the final maturation stage, fibroblasts and vascular cells undergo apoptosis and a mature scar is formed. Collagens are the most abundant proteins in the extracellular matrix and are critical in all stages of the healing process. Both excessive activity of collagen-degrading proteases or deficient collagen production during the inflammatory phase may result in an increased incidence of cardiac rupture or ventricular dilatation. 6 Successful wound healing and remodeling after a myocardial infarction (MI) thus requires a delicate balance of collagen production as well as degradation, yet the regulators of fibrillogenesis after MI are still poorly understood.
Osteoglycin has been implicated in a variety of biological processes such as bone formation, 7 cochlear development, 8 preterm labor, 9 tumor biology, 10 corneal transparency, 11 and skin integrity. 12 Recently, it was identified as a marker of cardiac hypertrophy in genome-wide analysis of the human heart. 13 Osteoglycin is a class III member of the small leucine-rich proteoglycans, a distinct group of extracellular proteoglycans that may affect matrix integrity through their central leucine-rich region, which is flanked by cysteine-rich domains.
14 Whether osteoglycin may regulate cardiac inflammation, collagen assembly, cardiomyocyte hypertrophy, or angiogenesis in the postinfarct healing process and hence attenuate the structural changes leading to cardiac rupture, dilatation, or HF is yet unknown.
The present study revealed that lack of proper collagen assembly in the absence of osteoglycin leads to increased infarct rupture and wall thinning after MI without affecting myofibroblasts differentiation, cardiac inflammation, cardiomyocyte hypertrophy, or angiogenesis. In contrast, osteoglycin gene overexpression with an adenoviral vector improved cardiac function after MI in wild-type (WT) mice. Importantly, circulating osteoglycin levels were increased in patients with ischemic HF as compared with patients with nonischemic HF and significantly correlated to markers of cardiac remodeling. Collectively, these preclinical and clinical data highlight the importance of osteoglycin in post-infarct-related HF.
Methods
An expanded Methods section is provided in the Online Data Supplement.
Animals and Surgery
Study protocols were approved by the ethical committee of the Catholic University of Leuven (Leuven, Belgium) and experiments were performed according to the Belgian legislation on the care and use of laboratory animals. Twelve-to 16-week-old osteoglycin null mice and their WT C57Bl/6J littermates were subjected to experimental MI and sham operations as previously described. 15 The production of osteoglycin null mice is described in detail elsewhere 12 ; mice were backcrossed to C57Bl/6J for >10 generations.
Human HF Samples
Age-matched human endomyocardial biopsy samples suggestive of myocardial ischemia and infarction were manually selected based on clinicopathological reports from the host university hospital (UZ Leuven, Leuven, Belgium) by an experienced pathologist (E.V.), who was not involved in the preclinical data acquisition. The ethical commission of UZ Leuven approved the study.
Human Plasma Samples
Plasma samples from patients with HF and non-HF were obtained from the Multi mARKer Emergency Dyspnea (MARKED) study, discussed previously. 16 Osteoglycin levels were quantified using a commercially available ELISA against osteoglycin (Cusabio). Plasma samples of patients with HF with and without MI were obtained from the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) study, described in detail previously. 17 Osteoglycin levels were measured using an ELISA microtiter plate prototype assay using antibodies against recombinant osteoglycin protein Ala20-Phe298 (accession no P20774, Roche Diagnostics).
Adenovirus-Mediated Osteoglycin Gene Transfer
Intravenous injection of 10 9 viral particles of adenovirus-overexpressing osteoglycin or control AdRR5 virus was performed in 11 to 13-week-old male C57Bl/6J mice by tail vein injection, 7 days before the onset of acute MI.
Histological and Morphometric Analysis
Mice were euthanized 3, 7, or 14 days after infarction. Cardiac tissue was fixed in 1% paraformaldehyde (Sigma) in PBS for 4 hours, postfixed in ethanol, dehydrated, and embedded in paraffin. Fourmicrometer-thick sections were made for routine histological and immunohistochemical stainings, as previously described. 6 
Electron Microscopy
After cannulation of the abdominal aorta, retrograde perfusion with 0.9% saline at physiological pressure during 1 minute was initiated, followed by perfusion with Karnovsky fixative. The heart was removed and 1 mm 3 cubes were dissected from the infarct zone. After overnight incubation in Karnovsky fixative, these cubes were washed and transferred to a 1% osmium tetroxide (Sigma) fixative solution buffered with PBS 0.1 mol/L pH 7.4. After dehydration, the cubes were embedded in Epon. Areas of interest were selected by light microscopy. Afterward, ultrathin sections were cut and examined in a Philips CM100 electron microscope (Philips).
Cardiac MRI
MR acquisitions were performed on a 7.05 T horizontal-bore (16 cm) MR scanner (Bruker, Germany), equipped with a 300-mT/m gradient system and working with 300.51 MHz for isotope 1H. MRI data were analyzed using QMass MR 7.1 and 6.2 (Medis, Leiden, The Netherlands).
Transthoracic Echocardiography
Echocardiography was performed in sedated mice (2% isoflurane, Ecuphar). M-mode views, long and short axis B-mode views were obtained using a 13-MHz transducer (i13L, GE Healthcare) on a GE Vivid7 (GE Healthcare) echocardiograph. Septal wall thickness (interventricular septum wall thickness), left ventricular (LV) posterior wall thickness, and LV internal diameters were measured at end-diastole and end-systole (d and s adjuncts, respectively). LV ejection fraction was calculated as described elsewhere. 
Cardiac Fibroblast Culture
Cardiac fibroblasts were isolated from 2-day-old neonatal Lewis rats as previously described. 19 Experiments were performed on secondpassage cells. For reduction of osteoglycin mRNA, cardiac fibroblasts were transfected with small interfering RNA (siRNA) against osteoglycin (ThermoScientific) or appropriate control siRNA (Life Tech) using Lipofectamine 2000 (Invitrogen). Thereafter, fibroblasts were treated with transforming growth factor-β (TGF-β, 10 ng/mL) for 30 minutes or 24 hours. To supplement cardiac fibroblasts with osteoglycin, recombinant osteoglycin (10 μg/mL; Sigma) was added for 24 hours. Thereafter, cells were incubated with TGF-β followed by protein extraction.
Western Blotting and Zymography
Snap-frozen tissue from the infarcted or remote zone or sham-operated animals was homogenized in RIPA (radioimmunoprecipitation assay) buffer. Phosphatase (Sigma) and protease (Complete, Roche) inhibitors were added according to the manufacturer's instructions. Lysates were resolved by SDS-PAGE and subsequently immunoblotted for osteoglycin (Abcam; R&D systems), phosphorylated and total SMAD2/3 (Cell Signaling Technologies), connective tissue growth factor (CTGF; Abcam), GAPDH or tubulin (Fitzgerald Industries) overnight at 4°C. Quantification was done using Image J software (NIH). For zymography, snap-frozen tissue was homogenized in extraction buffer using a rotor-stator homogenizer. After electrophoresis (Novex 10%, Invitrogen), gels were renatured and developed as previously described.
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RNA Isolation and Expression
RNA was isolated from the border zone or sham-operated animals with the miRVana kit (Ambion) according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed with the miScript cDNA synthesis kit (Qiagen). Real-time quantitative PCR was performed with SYBR green mix (Applied Biosystems) on an ABI Prism 7500 (Applied Biosystems). GAPDH was used as a housekeeping gene.
Statistical Analysis
Data are expressed as mean±SEM. All histological measurements were performed in duplicate on consecutive sections. Normal distribution of continuous variables was tested with the method of Kolmogorov and Smirnov. An unpaired Student t test was used when groups passed the normality test, when comparing 2 groups. For multiple comparison analysis a 2-way ANOVA using Fisher least significant difference test was used. Survival analysis was performed using the log-rank test. A 2-sided P value of <0.05 was considered statistically significant, using Prism as statistical software. Human plasma results are presented as frequencies (%), mean±SD, or median (interquartile range), as appropriate. Baseline characteristics and osteoglycin levels were compared between cases and controls using t test, Mann-Whitney test, or Pearson χ 2 , as appropriate. To adjust for clinical covariates, multiple linear regression was performed using osteoglycin (log transformed because levels were not normally distributed) as dependent variable and correcting for possible confounding baseline characteristics using backward stepwise selection. Spearman nonparametric correlations were calculated to assess the correlation between osteoglycin and other markers/parameters. The association of osteoglycin, divided into quintiles to deal with linearity assumption, with survival was analyzed by Cox proportional hazard regression models. A 2-sided P value of 0.05 was considered to be statistically significant, using SPSS software.
Results
Osteoglycin Expression Increases in Experimental Ischemic Heart Disease
Using a mouse model of permanent coronary occlusion, spatiotemporal changes in osteoglycin expression after MI were evaluated. Osteoglycin mRNA expression was low in sham-operated LV, as well as in infarcted and remote LV tissue in the early phase after MI (3 days), whereas its mRNA levels was only strongly upregulated in the infarcted area at 7 and 14 days ( Figure 1A ). In the infarcted area, osteoglycin protein levels remained unchanged 3 days after MI but significantly increased by 14 days after infarction ( Figure 1B) . Osteoglycin protein levels in the noninfarcted remote LV remained low both early and late after MI ( Figure 1B) . Immunohistochemistry confirmed that osteoglycin expression was low to absent in sham-operated LV but abundantly expressed in the infarct zone at 14 days and associated with areas of collagen deposition ( Figure 1C) . Notably, staining intensity was highest in dense connective tissue, indicating osteoglycin colocalization with tightly packed collagen. In normal myocardium, osteoglycin is produced in low amount in cardiomyocytes ( Figure 1D , white arrow) and nonmyocytes (black arrow). After MI, a robust increase in osteoglycin expression occurs in the infarct scar because of extracellular deposition and intracellular expression in elongated cells within the infarct, which morphologically resemble myofibroblasts. No changes are seen in cardiomyocyte osteoglycin expression bordering the infarct zone. Human osteoglycin expression in endomyocardial biopsy sections from patients with healed MIs occurs in the extracellular space and colocalized with collagen, similar to the murine model ( Figure 1E and 1F), and the amount of osteoglycin immunostaining found within the fibrotic scar was significantly higher in male patients as compared with female patients (Figure 1G ; n=15; P=0.02). In summary, osteoglycin expression is low in healthy myocardium and during the early wound-healing phase, yet its expression is significantly induced within the infarcted area during scar maturation.
To further translate our overall finding to the human situation, osteoglycin plasma levels were determined in a cohort of HF (n=159) patients with or without a previous history of ischemic heart disease (clinical characteristics in Online Figure 1H ).
Osteoglycin Is Necessary to Protect Against Cardiac Rupture and Dysfunction After MI
Absence of osteoglycin in mice resulted in a strong increase in mortality after MI (Figure 2A ; 14/48) as compared with WT mice (3/50; P=0.001). Mortality did not differ when comparing osteoglycin heterozygous mice (3/59; 5%) with WT mice (3/50; 6%; P=0. 8) , indicating that partial expression of osteoglycin is sufficient to prevent cardiac rupture and related mortality. However, mortality was sex dependent: 40% (12/30) of male osteoglycin null mice died within 14 days after MI, as compared with 4% (1/26) of male osteoglycin WT mice (P=0.0007; Online Figure IA) . Mortality was more prevalent in female osteoglycin null mice than in osteoglycin female WT mice after MI (2/18 versus 2/24, respectively), but this difference was not statistically significant (P=0.1; Online Figure IB ). On postmortem examination, pericardial bleeding because of cardiac rupture was the predominant cause of death in male osteoglycin null animals ( Figure 2B ); Figure 1 . Osteoglycin (OGN) expression is induced during ischemic heart disease. A, OGN mRNA expression increased in the infarcted area after myocardial infarction (MI) at 7 and 14 days as compared with the remote zone, sham-operated left ventricular (LV) and 3 days after MI (n≥4 per group). Transcript levels in the remote zone at 3, 7, and 14 days were comparable with the expression pattern in sham-operated LV. B, Western blot analysis showing OGN protein levels in the infarcted area of the LV in sham-operated mice as compared with 3 and 14 days after MI. Quantification of OGN protein levels showed an increase in the infarcted area after MI at 14 days, as compared with the remote region. Levels in the remote zone at 3 and 14 days were comparable with the expression pattern in sham-operated LV tissue (n=3 per group; *P<0.05 vs sham, †P<0.05 vs infarcted area 3 days after MI; ‡P<0.05 vs remote area). C, Immunohistochemical analysis of sequential tissue sections stained with hematoxylin-eosin, sirius red, and OGN antibody in a sham-operated OGN wild-type (WT) mouse and 14 days after MI in an OGN WT mouse. OGN expression was increased after MI in the infarcted regions and associated with collagen deposition. Representative image of a group, size n=3, scale bars=100 μm. D, OGN is expressed by cardiomyocytes and nonmyocytes in sham animals; after myocardial infarction, OGN expression robustly increases in the infarct scar. E, Representative images of OGN expression in human ischemic heart disease. OGN expression was found in areas with collagen deposition in post-MI and chronic ischemia biopsies (n=6; scale bars=100 μm). F, Endomyocardial biopsies from post-MI patients were quantified for the OGN content found within the collagen deposition in the scar tissue. Representative images for the female and male groups are shown. G, Quantification of OGN staining within the infarct showed a significant decrease in the amount of OGN found in the scar tissue of female patients vs male patients (P=0.02; n=15). H, OGN circulating levels are significantly higher in patients with heart failure with reduced ejection fraction with a history of MI (n=77) as compared with those with no history of MI or coronary artery disease (CAD; n=82; P=0.03). IHC OGN indicates immunohistochemical staining of OGN.
histological analysis showed coagulative necrosis interspersed with foci of intramural hemorrhage, white thrombi, and a dissecting hematoma ( Figure 2C ). Thus, osteoglycin has an essential role in maintaining infarct scar integrity and overall survival after MI.
Lack of Osteoglycin in Surviving Mice Leads to Infarct Thinning and Expansion and Cardiac Dysfunction
Conventional echocardiography (Online Tables I and II) as well as the more sensitive cardiac MRI (sham and 7 days after MI; Table 1 ) were performed to assess cardiac function. Neither echocardiography nor cardiac MRI revealed differences in cardiac function or dimensions at baseline and confirmed a decrease in cardiac function after MI in all groups. Whereas echocardiography did not show a significant difference in cardiac ejection fraction or end-diastolic 2-dimensional diameter in osteoglycin null compared with WT mice after MI (Online Tables I and II) , the more sensitive cardiac MRI revealed a further decrease in ejection fraction and increase in end-diastolic volume in osteoglycin null compared with WT mice (Table 1) . Impaired cardiac function in the absence of osteoglycin was further confirmed by significantly higher normalized lung weights in the osteoglycin null compared with WT mice (Table 2 ). In conclusion, the absence of osteoglycin resulted in increased cardiac dilatation and failure in the early remodeling phase after MI. ) . B, Mortality because of cardiac rupture was more prevalent in OGN null mice (59.3% incidence of death and 69% incidence of rupture) than OGN WT mice after MI (14.3% incidence of death and 50% incidence of rupture). C, The left ventricular wall rupture was visible macroscopically and was confirmed on a microscopic level with a hematoxylin and eosin staining of the infarcted area after MI in OGN null mice (middle). Right, Dissecting hematoma (arrowhead) and intramural hemorrhages (asterisks) surrounded by white thrombi (scale bars, 100 μm). D, The number of GR1 + cells (neutrophils) increased significantly in the infarcted area after 3 days but there were no differences between OGN WT and null mice. Similarly, there was an induction of CD68 + cells (monocytes) infiltrating into the infarcted area 3 days after MI but no differences were seen between OGN WT (n=10) and OGN null mice (n=9). E, Desmin staining illustrated the cytoskeletal changes in the cardiomyocytes along the border region after MI, yet no differences were observed between OGN WT and null mice. (scale bar, 50 μm). F, Cardiomyocyte area, assessed by laminin staining, showed no between genotype difference in cardiomyocyte hypertrophic response. G, The expression of the myofibroblast marker α-smooth muscle actin (ASMA) increased significantly 3 and 14 days after MI, but no differences were observed between OGN WT and null mice. H, Sirius red staining did not show differences in the amount of collagen deposition between OGN WT and OGN null infarcts at 14 days after MI (upper). Sirius red polarization microscopy revealed well-aligned and tightly packed (orangered [OR]) collagen fibers in the OGN WT infarcts but less mature fibers (yellow-green [YG]) in the OGN null infarcts (scale bars, 100 μm; lower). I, Quantification of collagen content (left) and (D) collagen quality (defined by OR:YG ratio, right). No differences in collagen content were observed but a significant difference in the collagen quality was measured in the OGN WT (n=6) vs the OGN null infarcts (n=7; P<0.05). January 30, 2015
Osteoglycin Null Infarcts Have Deficient Scar Maturation and More Loosely Assembled Collagen Fibers After MI
To further characterize the morphological and cellular differences in infarct healing between osteoglycin null and WT mice, mice were euthanized at 3 days where inflammation is most prominent and at 14 days after MI where fibrosis and tissue maturation take place. Sham-operated animals showed no differences between genotypes in LV circumference, CD45 staining cells (leukocytes), degree of collagen deposition, and CD31 staining vessels (capillaries; Table 2; Online Tables III  and IV) . Despite an increase in CD45
+ leukocyte infiltration at 3 and 14 days after MI, this did not differ between osteoglycin WT and null mice ( Table 2; Online Tables III and IV) . Because increased inflammation may trigger enhanced proteolytic matrix degradation and myocardial disruption, the inflammatory response was further characterized at 3 days after infarct, yet there were no differences between genotypes in both GR1 + (neutrophils) and CD68 + (monocytes/macrophages) cellular infiltrates ( Figure 2D ). Desmin content ( Figure 2E ) and cardiomyocyte cross-sectional area ( Figure 2F ; Online Figure IC ) in the remaining viable cardiomyocytes after MI were similar in the osteoglycin null compared with WT mice, suggesting that cardiomyocyte behavior and stress 21 did not differ between genotypes. Furthermore, relative infarct size, infarct thickness, capillary density (CD31 + vessels; Table 2 ), or myofibroblast cell content ( Figure 2G ) did not significantly differ between the genotypes at 3 or 14 days after MI. Finally, calcium deposition within the infarct, as visualized by polarized light of an alizarin red staining (Online Figure ID) , was unaffected by the absence of osteoglycin. However, at 14 days after MI the osteoglycin null mice had significantly greater absolute infarct length and LV circumferences than the osteoglycin WT mice ( Table 2 ; Online Table IV ). These data suggest that lack of osteoglycin results in infarct expansion on ischemic injury, as there were no differences in ventricular dimensions before infarction. Furthermore, the amount of collagen in the infarcted area did not differ (Figure 2H and 2I; Table 2; and Online Tables III  and IV) . On collagen maturation during proper infarct healing, the orange-red collagen fibers gradually replace the yellowgreen fraction 22 and thus loosely assembled thin collagen fibers (yellow-green) disappear and thick, tightly packed collagen (orange-red) appears. The ratio of tightly packed versus thin fibers (orange-red:yellow-green) was significantly lower in osteoglycin null as compared with the WT infarcts (Figure 2H and 2I; Table 2; and Online Tables III and IV) .
Osteoglycin Does Not Modulate Myofibroblast Behavior But Directly Interacts With Collagen to Promote Collagen Polymer Formation
To study the effect of osteoglycin on myofibroblast biology, cultured myofibroblasts were stimulated with TGF-β, a pivotal profibrotic cytokine during MI, 23 either after reduction of osteoglycin mRNA by siRNA or after supplementation of the culture medium with recombinant osteoglycin (Figure 3 ). Short-term (30 minutes) TGF-β treatment resulted in a significant increase in the ratio of phosphorylated SMAD2/3 (pSMAD2/3) to total SMAD2/3 in control siRNA-transfected myofibroblast; lower protein levels of osteoglycin did not significantly alter the effect of TGF-β on SMAD2/3 signaling in myofibroblasts ( Figure 3A and 3B ). Long-term (24 hours) TGF-β treatment resulted in a comparable increase in CTGF in control siRNA and osteoglycin siRNA-transfected myofibroblasts ( Figure 3A and 3C ). Comparable changes of pSMAD2/3/total SMAD2/3 and CTGF were observed in untreated and osteoglycin supplemented myofibroblasts ( Figure 3D and 3E) . Taken together, these in vitro data indicate that osteoglycin absence or supplementation do not alter myofibroblast biology nor growth factor signaling during profound stimulation with TGF-β.
To study whether osteoglycin could affect the production of collagen subtypes, beside affecting its cross-linking and quality, we determined collagen I and III mRNA levels, as well as the transcript levels of their intracellular and extracellular metabolizing enzymes, procollagen-lysine 2-oxoglutarate 5-dioxygenase 1 and 2, lysyl hydroxylase, bone morphogenic protein-1, CTGF, and C-endopeptidase (ADAMTS2) 14 days after MI (Online Table V ). Only transcript levels of collagen I, III, CTGF, and procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 significantly increased after MI both in osteoglycin WT and in null mice, but these increases did not significantly differ between genotypes. Next, transcript levels of collagen-degrading enzymes matrix metalloproteinase (MMP)-2 and MMP-9 and their regulators tissue inhibitor of matrix metalloproteinase (TIMP)-1, TIMP-4 were measured, as well as enzymatic activity of MMP-2, in the infarcted areas of the heart at 14 days after MI (Online Table V ). MMP-2 activity and TIMP-1 levels did increase at 14 days after MI but no differences between genotypes were observed. In conclusion, osteoglycin had no detectable influence on the absolute collagen abundance in the infarct scar nor did it affect collagen metabolism or degradation.
Coincubation of collagen and osteoglycin readily enhanced polymerization of collagen fibers and dense collagen mesh formation, macroscopically evident as a gelatinous mass; this plugging was minimal when collagen was incubated alone ( Figure 3F) . Quantification of the collagen plugs revealed a significantly higher density when collagen and osteoglycin were coincubated as compared with collagen alone ( Figure 3G ). To ensure that equal amounts of collagen were incubated in both conditions, we loaded the samples onto an electrophoresis gel and visualized all proteins with Coomassie Blue, showing no between-sample difference in total collagen. Finally, visualization of the collagen plugs by scanning electron microscope revealed osteoglycin abundantly surrounding each collagen fibril, creating a tighter collagen network ( Figure 3H) . Thus, in vitro we demonstrated a direct interaction of osteoglycin with collagen, as the absence of osteoglycin repeatedly created only a small dense nucleus of irregular collagen fibrils, whereas combining it with osteoglycin resulted in a voluminous and equally spaced mesh of uniform fibrils. These data corroborate a role for osteoglycin in nonenzymatic cross-linking of collagen fibers to enhance matrix stability. Finally, ultrastructural analysis with transmission electron microscopy confirmed that osteoglycin null infarcts had disorganized collagen fibers ( Figure 3I ). Although the mean collagen fiber diameter and fiber density were similar in osteoglycin WT and null infarcts, the distributions of fiber diameters and densities were markedly different between both genotypes ( Figure 3J ). In osteoglycin WT infarcts, fibers manifested with a uniform cross-sectional diameter and density, whereas fibers in osteoglycin null infarcts manifested a larger diameter range and thus a larger proportion of relatively small and large fibers. We therefore concluded that scar maturation is impaired in the absence of osteoglycin.
Adenoviral Overexpression of Osteoglycin Protects Against Cardiac Dilatation and Dysfunction After MI in WT Mice
To demonstrate the beneficial role of osteoglycin in MI healing, we first determined the effects of adenoviral overexpression of osteoglycin on cardiac dysfunction and healing after MI in WT mice. We ensured stable osteoglycin overexpression in the blood by a single injection of a replication-deficient adenoviral vector-containing mouse osteoglycin (AdenoOsteoglycin) 1 week before MI as compared with an empty vector (AdenoControl). Whereas osteoglycin expression in plasma was completely absent in AdenoControl-injected mice, osteoglycin plasma levels significantly increased in the mice injected with the active vector (AdenoOsteoglycin; Figure 4A and 4B). After adenoviral osteoglycin overexpression in WT mice, there was a trend toward statistically significant improved survival 14 days after MI (20/20) as compared with AdenoControl-injected WT mice (17/20; P=0.08; Figure 4C ). Adenoviral osteoglycin overexpression did not significantly alter cardiac inflammatory cell recruitment ( Figure 4D ; Online Table VI) , myofibroblast differentiation ( Figure 4E ), or cardiomyocyte desmin content ( Figure 4F ) 3 or 14 days after MI in WT mice. Osteoglycin overexpression did double the ratio of thick orange-red to thin yellow-green fibers as compared with the empty adenoviral vector-treated mice ( Figure 4I and 4J) without affecting the collagen content in the infarcted region ( Figure 4G and 4H) . The enhanced collagen maturation on osteoglycin overexpression resulted in significantly less ventricular dilatation and an improved ejection fraction 14 days after MI (Table 3) .
We postulated that we might be able to rescue the abnormal collagen maturation and subsequent cardiac rupture in the affected osteoglycin null mice by performing a similar adenoviral osteoglycin overexpression (Online Figure II) . Despite successful overexpression of circulating osteoglycin in the osteoglycin null mice there was no improvement in the survival rate after MI (Online Figure IIA) . Although there was still a poorer collagen quality observed in the osteoglycin null mice as compared with the WT mice (Online Figure IIB and IIC) , there was no improvement with the osteoglycin-expressing adenoviral vector. Western blot analysis revealed that adenoviral overexpression increased osteoglycin protein levels in the infarct scar of osteoglycin null animals, yet these levels were still significantly lower than osteoglycin protein levels in the infarct scar of osteoglycin WT animals injected with an empty vector (Online Figure IIE) . The amount of osteoglycin thus obtained was insufficient to rescue the pathophysiological consequence of a complete lack of osteoglycin in the complexly organized extracellular matrix. Overall, these data show that osteoglycin overexpression under normal WT conditions may help to improve cardiac function and decrease dilatation after MI through enhancing the collagen quality in the scar.
Osteoglycin as a Biomarker for Ischemic HF, Survival, and Cardiac Remodeling
Circulating osteoglycin levels in a small group of nonfailing and failing heart patients 16 (MARKED study) were analyzed and osteoglycin could be detected in 11 of 39 patients with HF (28%), whereas osteoglycin was only detected in 4 of 36 nonfailing patients (11%; P=0.0856). Detectability bias excludes any quantification of absolute osteoglycin levels in the nonfailing patients.
In a cohort of patients with HF (TIME-CHF study), osteoglycin levels were significantly higher in patients with HF with a history of MI as compared with patients with HF with no history of coronary artery disease ( Figure 1H ). Furthermore, patients with MI were more often men, had more often diabetes mellitus, a lower heart rate, and a trend toward higher creatinine levels when compared with controls (Online Table  VII ). Therefore, we corrected for these confounders in a multivariable linear regression model, which revealed that history of MI was an independent determinant of osteoglycin Higher levels of osteoglycin were associated with significantly increased 18-month overall mortality (hazard ratio, 9.73; 95% confidence interval=2.85-33.29 for fifth compared with first quintile; Wald=25.3; P<0.001), both in MI cases and in controls (P<0.01 in both groups, P for interaction=0.56). Osteoglycin levels correlated significantly to levels of interleukin-6 and type I procollagen in the whole cohort as well as in patients with an MI history (Table 4) , demonstrating an association of osteoglycin with fibrosis and inflammation in HF in general. Finally, osteoglycin levels correlated significantly and negatively to LV end-systolic volume in the subset of patients with HF with a history of MI, yet not in the general HF population (Table 4 ). P=0.08). D, There was no effect of OGN overexpression on the amount of leukocytes present in the infarcts at 3 or 14 days after MI. E, α-smooth muscle actin (ASMA) levels increased significantly 3 days after infarction only to decrease at 14 days after MI, with no significant differences between AdCtrl and AdOGN. F, Representative images of desmin immunohistochemistry staining illustrated the cytoskeletal changes in the cardiomyocytes along the border region after MI but showing no differences between AdOGN-treated vs AdCtrl-treated mice. G, Representative images of the collagen presence in the infarcted area of AdCtrl and AdOGN-treated mice 14 days after MI. H, Quantification of collagen content using Sirius red staining in the infarcted area 14 days after MI showed no differences in total collagen content. I, Using Sirius red polarization microscopy, more orange-red (OR) collagen fibers were seen in the AdOGN-treated mice as compared with the AdRR5-treated mice. J, Quantification of the collagen quality (OR/yellow green [YG] ), where a significant difference in the collagen quality was measured in the AdOGN (n=9) vs the AdCtrl infarcts 14 days after MI (n=8; P<0.001; scale bar, 50 μm).
Discussion
Our study is the first to demonstrate a critical role for osteoglycin in infarct healing through direct regulation of collagen maturation by nonenzymatic cross-linking. Osteoglycin is abundantly expressed in fibrotic areas and is found in tightly packed collagen in human and murine infarcts. Its absence results in impaired collagen quality in the infarcted area, causing LV expansion and cardiac rupture. Post-MI mortality proved sex-dependent, preferentially affecting male mice. This is a common observation after experimental MI, previously linked to differences in angiogenesis, extracellular matrix remodeling, and inflammatory response. 24, 25 The absence of osteoglycin does not alter the collagen quantity, identifying a direct effect of osteoglycin in promoting collagen maturation. This conclusion is further supported by adenoviral vector-mediated overexpression of osteoglycin in WT mice resulting in enhanced collagen maturation in the infarcted area, reduced adverse remodeling, and improved cardiac function. Extensive exploration of inflammation, myofibroblast differentiation, and signaling, as well as cardiomyocyte cytoskeletal properties and hypertrophy could not reveal differences in these factors that could contribute to increased cardiac rupture, mortality, or failure in osteoglycin null mice. Although previous studies demonstrated a role for osteoglycin in cardiac hypertrophy after angiotensin infusion, 13 our data do not support a role for osteoglycin in cardiomyocyte hypertrophy. This may be because of the differences in the pathophysiology of the models. In the study performed by Petretto et al, 13 hypertrophy was assessed by LV mass rather than a histological analysis of cardiomyocyte cross-sectional area. Furthermore we, and others, have found that cardiac fibroblasts express high levels of osteoglycin as compared with cardiac myocytes. Therefore, we investigated the role of osteoglycin in myofibroblast signaling and its putative influence on TGF-β signaling and CTGF expression. Osteoglycin inhibition or its addition failed to influence fibrotic signaling pathways. Another small leucine-rich proteoglycans, biglycan, has been shown previously to support the expansion of tendon stem/progenitor cells 26 and although we cannot exclude that a survival difference after MI in mice is because of cardiac myofibroblast progenitor cells, it is highly unlikely. Undetectable levels of myofibroblast progenitor marker Islet-1 in the infarcted tissue (data not shown), and the time frame of adverse cardiac events do not favor a role for osteoglycin in fibroblast progenitor cell function.
Osteoglycin is able to affect the capacity of collagen fibrils to physically interact to form a collagen mesh as demonstrated by our in vitro analysis. The structure of collagen itself drives self-assembly, 27 but several small molecules in the extracellular matrix, such as biglycan, modulate this process and hence can be regarded as extracellular chaperones ensuring a sturdy collagen matrix in infarct remodeling. 28 The maturation of collagen fibers into fibrils is a complex process, characterized by covalent cross-linking of collagen polymers into fibers by means of enzymatic and nonenzymatic steps; however, noncovalent interactions further strengthen the macromolecular structure. Our data exclude a role for osteoglycin in collagen formation through an increase of the enzymatic cross-linking of collagen fibers, as the metabolizing collagen enzymes did not significantly differ between studied genotypes. In contrast, osteoglycin directly increases collagen fibril cross-linking through direct physical interaction, as shown by our in vitro data and ultrastructural analysis. These data are supported by 3-dimensional reconstruction tomography of the extracellular matrices in the cornea 29 as well as dedicated staining techniques proposed by Scott et al, 30 which have convincingly shown that proteoglycans can bind to collagen fibrils, allowing the glycosaminoglycan attached to the proteoglycan backbone to form bridges and hence result in uniaxial, well-aligned fibrils. This reversible, noncovalent bridging is either through hydrogen bonds between the glycosaminoglycan chains or hydrophobic interactions 31 and guarantees proper assembly of connective tissue. Under pathological conditions such as after a MI, it is essential to ensure a well-assembled uniform scar and here we demonstrated the critical contribution of nonenzymatic collagen cross-linking, modulated by osteoglycin, to this process. The detection of osteoglycin in plasma of patients with HF and its strong association with a history of MI as well as biomarkers of inflammation and fibrosis is interesting and translates our preclinical study to the human HF situation. Although our analysis of the MARKED study samples showed a trend to significance and it is tempting to speculate that osteoglycin levels are higher in patients with HF as opposed to patients with non-HF as osteoglycin was below detectable levels in more nonfailing patients as compared with patients with HF, caution must be taken as patient groups were small. We found that osteoglycin levels are indicative of adverse outcome in patients with HF during an 18-month follow-up period, as higher plasma levels correlated with increased mortality and inversely with LV end-systolic volume, suggestive of adverse remodeling. These clinical findings do not contradict our preclinical data as increased levels of osteoglycin hint at ongoing fibrosis and matrix remodeling. Although in essence this should be beneficial as its prevents dilatation, fibrosis and remodeling have also been shown to strongly correlate with the increased incidence of arrhythmias and sudden cardiac death. 32 As such, osteoglycin is reminiscent of the dichotomous nature of brain natriuretic peptide, which is upregulated in HF in response to LV overload. Despite brain natriuretic peptide itself having a positive effect (natriuresis, vasodilatation, and inhibition of the renin-angiotensin and sympathetic systems), it is indicative of a worse prognosis, most likely because it reflects the initial problem of overload. 33 We therefore postulate that elevated osteoglycin levels partially prevent LV dilatation but cannot fully prevent the negative effect on survival. Our retrospective clinical data thus suggests a role for osteoglycin as a prognostic biomarker in ischemic heart disease. Of course, additional prospective clinical work is essential to confirm osteoglycin as either a prognostic biomarker or to identify those patients requiring intensified follow-up and treatment to prevent major adverse cardiac events with osteoglycin as a treatment target. In conclusion, our study is the first to reveal that osteoglycin after MI is essential for appropriate collagen maturation and infarct healing, and that osteoglycin is a potential biomarker for ischemic HF.
